These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 34899631)

  • 1. Potential Use of CRISPR/Cas13 Machinery in Understanding Virus-Host Interaction.
    Bayoumi M; Munir M
    Front Microbiol; 2021; 12():743580. PubMed ID: 34899631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Mechanisms of RNA Targeting by Cas13-containing Type VI CRISPR-Cas Systems.
    O'Connell MR
    J Mol Biol; 2019 Jan; 431(1):66-87. PubMed ID: 29940185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structures, mechanisms and applications of RNA-centric CRISPR-Cas13.
    Yang H; Patel DJ
    Nat Chem Biol; 2024 Jun; 20(6):673-688. PubMed ID: 38702571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cas13-induced cellular dormancy prevents the rise of CRISPR-resistant bacteriophage.
    Meeske AJ; Nakandakari-Higa S; Marraffini LA
    Nature; 2019 Jun; 570(7760):241-245. PubMed ID: 31142834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Applications of CRISPR/Cas13-Based RNA Editing in Plants.
    Kavuri NR; Ramasamy M; Qi Y; Mandadi K
    Cells; 2022 Aug; 11(17):. PubMed ID: 36078073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cas13d: A New Molecular Scissor for Transcriptome Engineering.
    Gupta R; Ghosh A; Chakravarti R; Singh R; Ravichandiran V; Swarnakar S; Ghosh D
    Front Cell Dev Biol; 2022; 10():866800. PubMed ID: 35433685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Engineering RNA Virus Interference via the CRISPR/Cas13 Machinery in Arabidopsis.
    Aman R; Mahas A; Butt H; Aljedaani F; Mahfouz M
    Viruses; 2018 Dec; 10(12):. PubMed ID: 30572690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Advances in the RNA-targeting CRISPR-Cas systems].
    Hong T; Luo Q
    Sheng Wu Gong Cheng Xue Bao; 2023 Apr; 39(4):1363-1373. PubMed ID: 37154311
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimization of specific RNA knockdown in mammalian cells with CRISPR-Cas13.
    Burris BJD; Molina Vargas AM; Park BJ; O'Connell MR
    Methods; 2022 Oct; 206():58-68. PubMed ID: 35987443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RNA Guide Complementarity Prevents Self-Targeting in Type VI CRISPR Systems.
    Meeske AJ; Marraffini LA
    Mol Cell; 2018 Sep; 71(5):791-801.e3. PubMed ID: 30122537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insights Gained from RNA Editing Targeted by the CRISPR-Cas13 Family.
    Liu L; Pei DS
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Review on the Mechanism and Applications of CRISPR/Cas9/Cas12/Cas13/Cas14 Proteins Utilized for Genome Engineering.
    Hillary VE; Ceasar SA
    Mol Biotechnol; 2023 Mar; 65(3):311-325. PubMed ID: 36163606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RNA-Targeting CRISPR-Cas Systems and Their Applications.
    Burmistrz M; Krakowski K; Krawczyk-Balska A
    Int J Mol Sci; 2020 Feb; 21(3):. PubMed ID: 32046217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cooperation between Different CRISPR-Cas Types Enables Adaptation in an RNA-Targeting System.
    Hoikkala V; Ravantti J; Díez-Villaseñor C; Tiirola M; Conrad RA; McBride MJ; Moineau S; Sundberg LR
    mBio; 2021 Mar; 12(2):. PubMed ID: 33785624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In silico optimization of RNA-protein interactions for CRISPR-Cas13-based antimicrobials.
    Park HM; Park Y; Berani U; Bang E; Vankerschaver J; Van Messem A; De Neve W; Shim H
    Biol Direct; 2022 Oct; 17(1):27. PubMed ID: 36207756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional Features and Current Applications of the RNA-Targeting Type VI CRISPR-Cas Systems.
    Perčulija V; Lin J; Zhang B; Ouyang S
    Adv Sci (Weinh); 2021 Jul; 8(13):2004685. PubMed ID: 34254038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery, classification and application of the CPISPR-Cas13 system.
    Nie X; Wang D; Pan Y; Hua Y; Lü P; Yang Y
    Technol Health Care; 2024; 32(2):525-544. PubMed ID: 37545273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A one-step platform for screening high-efficient and minimal off-target CRISPR/Cas13 crRNAs to eradicate SARS-CoV-2 virus for treatment of COVID-19 patients.
    Li PY; Li SQ; Gao SG; Dong DY
    Med Hypotheses; 2022 Feb; 159():110754. PubMed ID: 35002020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A short overview of CRISPR-Cas technology and its application in viral disease control.
    Ghorbani A; Hadifar S; Salari R; Izadpanah K; Burmistrz M; Afsharifar A; Eskandari MH; Niazi A; Denes CE; Neely GG
    Transgenic Res; 2021 Jun; 30(3):221-238. PubMed ID: 33830423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in CRISPR-Cas systems for RNA targeting, tracking and editing.
    Wang F; Wang L; Zou X; Duan S; Li Z; Deng Z; Luo J; Lee SY; Chen S
    Biotechnol Adv; 2019; 37(5):708-729. PubMed ID: 30926472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.